GA-KORE-ABLE-DEVICE
27.2.2017 09:03:16 CET | Business Wire | Press release
KORE , the people powering the Internet-of-Things (IoT) innovations and opportunities, and Able Device , a pioneer in SIM-based IoT and M2M application technology, today announced an agreement to deploy enterprise customer pilots that embed Able Device’s flagship offering, SIMbae, on KORE IoT SIMs (Subscriber Identity Modules). SIMbae, a new and innovative SIM-based solution utilizes established 3GPP standards and provides valuable tools on KORE SIMs to solve common IoT device deployment issues related to network connectivity, commercial and service requirements, and data roaming.
“Large scale deployments of IoT services, particularly global services, must be driven with greater ease and reliability of roll out,” said Alex Brisbourne, KORE CEO. “The goal is to move as close as possible to plug and play deliveries as well as simplified, automated, service connectivity around the globe. A perfect complement to our subscription management/eSIM solutions which already have over 1.2m connections depending upon it, integrating SIMBae provides a further level of automated service assurance,” concluded Brisbourne.
With deployments beginning in March 2017, customer pilots will initially center around three IoT use cases:
- The first case focuses on troubleshooting an IoT device that is not reporting into the server. In this scenario, SIMbae reports mobile-specific network information such as signal strength, neighboring cells, and other key metrics to determine the connectivity issue.
- A second case addresses an IoT device roaming onto a network that doesn’t meet commercial or service requirements and is then resolved through implementing SIMbae’s Dynamic PLMN Manager.
- The third scenario deployed during the pilots will utilize SIMbae’s Packet Data Reporter to change networks when a device roams onto a network that doesn’t support data roaming. Additionally, by embedding these tools on KORE’s SIMs and utilizing 3GPP standards, a consistent high level of application and communications security is achieved.
“We’re extremely excited to enter into real world, enterprise commercial pilots with KORE as they were the first service provider we approached when SIMbae was conceived,” stated Roger Dewey, CEO and Founder of Able Device. “The reason for this was KORE’s strong vision and early leadership in offering the enterprise market high value services to deploy IoT projects in a very flexible model.” He continued by saying, “Able Device and KORE share a philosophy centered on ease of development, deployment, security, and operation for mobile IoT applications. The standard SIM is the perfect vehicle for realizing that vision on a mass scale, but the SIM is not enough as it needs to be coupled with enterprise centric services.”
To visit with KORE during Mobile World Congress 2017 to learn more about these new and innovative SIM-based tools and how can they can simplify and secure your IoT deployments, contact Jacqueline Tait at jtait@korewireless.com .
About KORE
KORE provides the connectivity and services that make the Internet of Things possible. Founded in 2003, KORE is the world’s largest managed network services provider specializing in Internet of Things (IoT) and Machine to Machine (M2M) markets. KORE provides the critical wireless IoT connectivity empowering application, hardware and wireless operator partners to rapidly bring new IoT and M2M innovations to market, with millions of active on-network units in more than 180 countries. KORE delivers choice, reliability and global native coverage through multi-carrier and Tier 1 carrier cellular and satellite network services – including LTE, GSM and CDMA - as well as advanced applications to easily manage IoT connected devices. KORE Position Logic software provides seamless location-based services (LBS) for businesses. KORE’s recent acquisition of Wyless makes the company one of the six largest providers of M2M/IoT services globally, inclusive of carriers.
For more information, visit www.koretelematics.com , read the KORE blog and connect with KORE on LinkedIn , Google+ , Facebook , Twitter , YouTube and Vimeo .
About Able Device
Able Device is a provider of technology for Mobile Network Operators (MNOs) and IoT service providers. Its flagship product SIMbae™ (short for "SIM based application engine") enables hosting of IoT device controls and applications on standard SIMs. In this new architecture, the SIM is transformed to an intelligent independent processor. As SIMbae utilizes established and common 3GPP SIM standards, IoT controls and applications implemented this way become device and carrier agnostic - with benefits including shorter time to market, reduced development cost, lower operating cost, and improved security. Based in Raleigh, NC, Able Device serves mobile network operators globally.
For more information, visit www.abledevice.com .
All products/services and trademarks mentioned in this release are the properties of their respective companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227005390/en/
Contact:
For KORE
MSLGROUP Boston
Joe
Palladino or Maggie Fairchild
+1 781-684-0770
kore@mslgroup.com
or
For
Able Device
Leigh Ann Ryals, +1 919-809-6822
info@abledevice.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
